<DOC>
	<DOCNO>NCT00615836</DOCNO>
	<brief_summary>The purpose study investigate long term efficacy safety several dos Melt formulation desmopressin broad population adult patient nocturia .</brief_summary>
	<brief_title>An Extension Study Investigating Efficacy Safety Fast-Dissolving ( `` Melt '' ) Formulation Desmopressin Treatment Nocturia Adults</brief_title>
	<detailed_description>FE992026 CS31 multicenter open-label extension study patient enrol Study FE992026 CS29 ( NCT00477490 ) complete least Visit 3E Part II study . The CS29 study structure 2 double-blind part ( Part I Part II ) . In Part I , initial 28-day treatment period , participant randomly assign 1 5 treatment group : placebo desmopressin Melt 10 μg , 25 μg , 50 μg , 100 μg . Immediately upon completion Part I study , participant active treatment continue Part II treatment approximately 1 6 month . Participants assign placebo Part I randomly assign 1 4 active treatment Part II , base re-randomization predetermined initial randomization ( maintain blind ) . Part II begin final visit Part I continue database Part I lock . Therefore , treatment duration Part II vary 1 6 month , depend upon participant enter . Upon completion Part II CS29 , participant give option participate open-label extension study ( CS31 ) . During CS31 , participant assign 10 μg dose switch high dose open-label manner among remain 3 high dos .</detailed_description>
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Written inform consent prior performance studyrelated activity . Was randomize Part II Protocol FE992026 CS29 ( NCT00477490 ) , entitle `` A Randomized , Double Blind , Placebo Controlled , Parallel Group , MultiCenter Study Double Blind Extension Investigating Efficacy Safety FastDissolving ( `` Melt '' ) Formulation Desmopressin Treatment Nocturia Adults '' complete least Visit 3E Part II ( Day 15 ) . Patients use loop diuretic ( furosemide , torsemide , ethacrynic acid ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>